Anti-CTLA-4 blockade also depleted intratumoral CTLA-4+ Treg cells by macrophages via ADCC in recent reports [17–19], which implies that CTLA-4 blockade can activate anti-tumor immunity in the presence of enough tumor-infiltrating lymphocytes (TILs). The gene discussed is CTLA4; the disease is neoplasm.